Clinical Oncology

This year’s focus will be on Clinical Oncology and two full day tracks will cover topics such as genetic predisposition, genetic causes and the environment, targeting the tumour environment, melanoma, lymphomas, non-melanoma skin cancer, rare skin tumours, as well as adverse effects of chemotherapies and targeted therapies.

Below is a preview of the stimulating topics that will be discovered and covered over two full days…

Day 1 – Thursday, 13 September

Clinical oncology: Genetic predisposition, genetic causes and the environment

  • Melanoma: Genetic testing for risk factors
  • Melanoma drivers
  • Molecular testing for targeted therapy: When and how
  • Genetic testing in histiocytosis and mastocytosis


Clinical oncology: Genetics, environment and clinical implications        

  • Squamous cell carcinomas: Mutations and clinical implications
  • Basal cell carcinomas: Mutations and clinical implications
  • Genetics of tumour syndromes
  • Oncogenic mutations and the environment: Clinical implications


Clinical oncology: Targeting the tumour environment     

  • Inflammation and carcinogenesis
  • Therapeutic targeting of the tumour microenvironment
  • CTLA4 or PD-1/PD-L1 antagonists: Their direct effects on tumour cells
  • Risks and behaviour of NMSC in transplant patients


Clinical oncology: Melanoma          

  • Checkpoint inhibitors
  • Acquired resistance: Mode of actions
  • Immunotherapies beyond PD-1 antagonists
  • Adverse effects of immunotherapies


Day 2 – Friday, 14 September

Clinical oncology: Lymphomas       

  • Classification of B- and T-cell lymphomas: Update
  • Biology and management of early stage CTCL
  • Late stage CTCL: Conventional and new treatments
  • Management of B-cell lymphomas


Clinical oncology: Non-melanoma skin cancer      

  • High risk SCC and BCC
  • Systemic therapies for BCC: State of the art
  • Systemic therapies for SCC: State of the art
  • Systemic therapies for Merkel cell carcinoma: State of the art


Clinical oncology: Rare skin tumours        

  • Management of angiosarcomas
  • Paget’s disease and Paget’s carcinoma: Diagnosis and treatment
  • Adnexal carcinoma: Diagnosis and treatment
  • Prevention and treatment of HPV-induced cancer of the skin and mucosa


Clinical oncology: Adverse effects of chemotherapies and targeted therapies   

  • Management of skin cancer in the immuno-suppressed patient
  • Cutaneous adverse reactions of frequently used chemotherapies
  • Cutaneous reactions to anti-EGFR agents
  • Cutaneous reactions to targeted therapies: BRAF/MEK, PI3 kinase and hedgehog inhibitors


The full programme with confirmed speakers is available here for viewing.

Beware of scams

Beware of scams

Please beware of scam companies pretending to offer accommodation and registration to the EADV Congress (adding a percentage of commissions)!

Only trust information from our official websites:




· (to contact the EADV Staff)

You have Successfully Subscribed!

Share This